Showing results (11-20 of 3,492) with videos related to
Sort By:
Pageof 350
Cancers|August 12, 2022
Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint InhibitorsZhening Zhang, Tong Xie, Changsong Qi, et al.Frontiers in Oncology|September 20, 2021
Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-AnalysisTong Xie, Zhening Zhang, Xiaotian Zhang, et al.Cancer Medicine|September 29, 2023
Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET-amplified gastric cancerZhening Zhang, Yiyi Yu, Tong Xie, et al.Medical Oncology (Northwood, London, England)|June 21, 2013
Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patientsJing Gao, Jun Zhou, Yanyan Li, et al.Cancer Chemotherapy and Pharmacology|May 23, 2013
Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysisZhi Peng, Qianqian Wang, Jing Gao, et al.Journal of Cancer Research and Clinical Oncology|November 16, 2020
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized studyYuan Zong, Jiajia Yuan, Zhi Peng, et al.Journal of Hematology & Oncology|April 24, 2026
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategiesYi Xie, Pengfei Guan, Dan Liu, et al.Frontiers in Oncology|June 18, 2021
Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint InhibitorYang Chen, Cheng Zhang, Zhi Peng, et al.The Oncologist|August 16, 2021
The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical TrialsTong Xie, Zhening Zhang, Changsong Qi, et al.BMC Cancer|July 19, 2019
Hyperprogression after immunotherapy in patients with malignant tumors of digestive systemZhi Ji, Zhi Peng, Jifang Gong, et al.Pageof 350